ebitda
30–40 pct
FY 2026
management target
VILLAGE FARMS INTERNATIONAL, INC.
Last · —$2.56-0.08 (-3.03%)live · yahoo · 1h ago
Market cap$313.05M—
P/E · TTM14.2fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $230.6M |
|---|---|
| Operating income | $16.2M |
| Net income | $10.1M |
| Free cash flow | $-23.3M |
| Operating margin | 7.0% |
| Net margin | 4.4% |
| Return on equity | 3.2% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strong BuyBuyHoldSellStrong Sell
Constructive quarter, but not a risk-free buy:
international exports rose 74% YoY to $20.9M, cannabis gross margin expanded to 51%, and cannabis adjusted EBITDA reached a record $15.3M at a 29% margin. The key tension is that reported consolidated adjusted EBITDA fell to $15.4M from $17.1M because of a prior-year settlement, while Canada is mature, domestic supply is returning, and management could not quantify Germany’s market growth or share gains; the stock merits a positive bias, but execution and valuation remain critical.
Themes
- International Exports
- Germany Cannabis
- Eu Gmp
- Delta 2 Expansion
- Groningen
- Canada Pricing
Near term
Germany remains the primary near-term catalyst: export sales increased 43% sequentially, but management provided no verified market-growth or market-share data despite analyst questioning.
Delta 2’s second-half conversion begins September 1, with management expecting 15 metric tons of incremental production in 2026; investors should watch whether added supply converts into revenue without eroding EU GMP pricing.
Groningen began cultivation in Q2 and is expected to reach full production by the end of Q1 2027, creating a potential growth step-up but also execution risk.
Second-half free cash flow is expected to improve as major expansion CapEx winds down, though inventory rose to $46.7M and trade receivables to $32.4M as international payment terms lengthened.
Longer term
The EU GMP platform is the central moat: Village Farms claims the world’s largest EU GMP-certified facility by compliant product volume, four of Germany’s top 10 strains, and the widest pharmacy distribution among cultivators. These are strategically valuable positions, but the market-share and distribution claims are primarily internal estimates rather than independently verified metrics.
Management targets a 30%-40% EBITDA margin over the long term, supported by scale, yield improvements, and lower cultivation costs. The 29% cannabis EBITDA margin is encouraging, but sustaining it as competitors add EU GMP capacity remains unproven.
The Netherlands opportunity could expand materially if the coffee-shop pilot is broadened; management cited nearly tenfold potential market expansion, but this depends on government policy and the still-developing pilot program.
Management expressed interest in greater European vertical integration and branded products, which could improve economics but would require additional capital and introduce acquisition or downstream execution risk.
Canada appears increasingly mature, with management characterizing growth as single digit and pricing as largely plateaued. Convenience categories may support mix, but returning supply in lower-value flower could pressure domestic pricing.
Red flags
Management could not verify German market growth, citing internal estimates ranging from 8% to 15%, and did not quantify its actual market share despite Germany driving most of the growth narrative.
Management was noncommittal when asked whether Village Farms would develop a European footprint, answering that it would discuss the matter offline. This leaves the long-term distribution and vertical-integration strategy under-specified.
Competitive pressure is not theoretical: management acknowledged that additional market entrants could create price pressure, while claiming EU GMP pricing remains strong. No forward pricing, volume, or customer-concentration data was provided.
International growth is consuming working capital: receivables increased materially because of longer export terms, while the company paid $17M of Canadian income taxes in the first half and drew CAD 8.3M on the Pure Sunfarms credit facility.
SG&A rose to $18.8M from $15.4M and represented 28% of sales versus 23% last year. Transfer-pricing changes explain part of the increase, but higher commercial spending could limit operating leverage.
The $73M cash balance includes a $15M equity placement, while the company also executed $7M of buybacks and carried roughly $40M of debt. Capital allocation is therefore supportive of liquidity but not entirely self-funded.
Texas entry remains unresolved: management said conditional licenses may not be final and that it still plans to be involved, but offered no concrete route, timing, or capital commitment.
Forward outlook
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest 10-K · 2025-03-13
- Net Margin Sharply Negative
Red flags
- Net Margin Sharply Negative — Net margin -10.7%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.05
Est. revenue
64.4M
Earnings transcripts
Press & signals
- GlobeNewswire
Village Farms Welcomes Initial Government Findings from the Netherlands Regulated Cannabis Program
- GlobeNewswire
Village Farms Appoints Deepak Anand to Lead Global Government Affairs
- GlobeNewswire
Village Farms Appoints Hamid Shekarchi as Interim Chief Financial Officer
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans